Role of Epigenetics in Cancer and Targeted Therapies for Oncologic Treatments

Martha Srinivas *

Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.

Salunkhe Pratiksha Sanjay

Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.

Londhe Pratima Manik

Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.

Vishal Bharat Babar

Dattakala Shikshan Sanstha Institute of Pharmaceutical Science & Research (For Girls), Swami-chincholi, Bhigwan, Pune, Maharashtra- 413130, India.

Koppula Maheshwari

Department of Pharmaceutics, Joginpally B.R Pharmacy College, Yenkapally (V), Moinabad(M), Telangana, JNTU, Hyderabad-500075, India.

*Author to whom correspondence should be addressed.


Abstract

DNA sequence has little bearing on the dynamic and heritable changes to the genome that occur in epigenetics. Both genetic and epigenetic alterations influence the development of cancer. There are several opportunities for therapeutic interventions because epigenetic modifications can be reversed. Many epigenetic drugs are currently used globally to treat conditions including leukemia and myelodysplastic syndrome. Owing to their malleability and vulnerability to outside factors, epigenetic modifiers are becoming intriguing targets for a number of cancer treatments. Recently, a large number of epi-drugs have been developed, and they may find application in clinical situations. The aforementioned initiatives to realize the potential of epigenetic medicines for efficient cancer treatment are summed up in this review. The maintenance of cell identity and the spatial and temporal regulation of gene expression depend on the proper coordination of epigenetic regulators. Both genetic and epigenetic changes contribute to cancer. The development of medications that target epigenetic regulators has advanced significantly over the past few decades, with numerous medications currently under assessment in research studies. In how they could be used to treat cancer. We also go over the preclinical and clinical outcomes of epigenetic medication combination therapies as well as other therapies including immune-based and targeted medicines.

Keywords: Heritable modifications, leukemia, myelodysplastic syndrome, epigenetic modifiers, epi-drugs, Malleability


How to Cite

Srinivas , Martha, Salunkhe Pratiksha Sanjay, Londhe Pratima Manik, Vishal Bharat Babar, and Koppula Maheshwari. 2024. “Role of Epigenetics in Cancer and Targeted Therapies for Oncologic Treatments”. Current Journal of Applied Science and Technology 43 (6):23-30. https://doi.org/10.9734/cjast/2024/v43i64383.

Downloads

Download data is not yet available.

References

Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;158:38–55.

Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62. Available:https://doi.org/10.1038/s41392-019-0095-0

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. View Article : Google Scholar : PubMed/NCBI2

Deans C, Maggert KA: What do you mean, ‘epigenetic’? Genetics. 2015;199:887–896. View Article : Google Scholar : PubMed/NCBI

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 2008;34(3):193-205.

Dupont C, Armant DR, Brenner CA. Epigenetics: Definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351–357. [PMC free article] [PubMed] [Google Scholar]

Javierre BM, Fernandez AF, Richter J. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20(2):170–179. [PMC free article] [PubMed] [Google Scholar]

Kouzarides T. Chromatin Modifications and Their Function. Cell. 2007;128:693–705. DOI: 10.1016/j.cell.2007.02.005

Jones PA, Baylin SB. The Epigenomics of Cancer. Cell. 2007;128:683–92. DOI: 10.1016/j.cell.2007.01.029

Shen H, Laird PW. Interplay between the cancer genome and Epigenome. Cell. 2013;153:38–55. DOI: 10.1016/j.cell.2013.03.008

Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands, Nature. 1990;346:818-822.

Esteller M. Epigenetics in Cancer. N Engl J Med. 2008;358:1148–59. DOI: 10.1056/NEJMra072067

Jones PA, Takai D. The Role of DNA Methylation in Mammalian Epigenetics. Science. 2001;293:1068–70. DOI: 10.1126/science.1063852

Dellafiore MA, Montserrat JM, Iribarren AM. Modified Nucleoside Triphosphates for In-vitro Selection Techniques, Frontiers Chem. 2016;4:18.

Singh Y, Murat P, Defrancq E. Recent developments in oligonucleotide conjugation, Chem. Soc. Rev. 2010;39: 2054-2070.

Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol. 2013;98(6):648-57. DOI: 10.1007/s12185-013-1407-8

Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2(1):71–86. [PubMed] [Google Scholar]

Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA. 1964;51:786–794. [PMC free article] [PubMed] [Google Scholar]

Martens JW, Margossian AL, Schmitt M, Foekens J, Harbeck N. DNA methylation as a biomarker in breast cancer. Future Oncol (London, England). 2009;5(8):1245–1256. [PubMed] [Google Scholar]

Han H, Wolff EM, Liang G. Epigenetic alterations in bladder cancer and their potential clinical implications. Adv Urol. 2012;2012:11. [PMC free article] [PubMed] [Google Scholar]

Simó-Riudalbas L, Esteller M. Cancer genomics identifies disrupted epigenetic genes. Hum. Genet. 2014;133:713–725. DOI:10.1007/s00439-013-1373-5 [PubMed] [CrossRef] [Google Scholar]

DiNardo CD, Cortes JE. Mutations in AML: Prognostic and therapeutic implications. Hematology (Am Soc Hematol Educ Program). 2016;2016(1):348-355.

Vobugari N, Heuston C, Lai C. Clonal cytopenias of undetermined significance: Potential predictor of myeloid malignancies. Clin Adv Hematol Oncol. 2022;20(6):375-383.

Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell. 2012;150(1):12-27.

Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726-734.

Jones PA, Baylin SB. The Fundamental Role of Epigenetic Events in Cancer. Nat Rev Genet. 2002;3:415–28. DOI: 10.1038/nrg816

Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA: A Cancer Journal for Clinicians. 2022;73(4):376–424. Available:https://doi.org/10.3322/caac.21765

Fardi M, Solali S, Farshdousti Hagh M. Epigenetic mechanisms as a new approach in cancer treatment: An updated review. Genes Dis. 2018;5(4):304- 311. DOI: 10.1016/j.gendis.2018.06.003

Tuerk C, Gold L, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science. 1990;249 (1990) 505-510.